Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of paliperidone palmitate injection in adult schizophrenia
ChiCTR2400092341Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xinxiang Medical University
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by The Second Affiliated Hospital of Xinxiang Medical University. Primary endpoints: Efficacy (PANSS) and Laboratory examinations. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2400092341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092341.